LETT APPL MICROBIOL 润色咨询

LETTERS IN APPLIED MICROBIOLOGY

出版年份：1985 年文章数：4104 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：2.9% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1094681, encodeId=4987109468180, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1094682, encodeId=67e5109468292, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847123, encodeId=918f84e12376, content=2018.06.01 投稿 <br> 2018.06.06 under review <br> 2018.07.25 accept subject to minor revision (25-jul-2018)，给一个月，二个审稿人，一共10来条问题。 <br> 2018.08.17 修回 <br> 2018.08.17 under review <br> 2018.09.04 accept (04-sep-2018) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Sun Sep 09 09:04:18 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552370, encodeId=bfa65523e044, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:51:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552369, encodeId=330f55236909, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:50:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547583, encodeId=91e854e583e1, content=审稿速度:3.0<br>经验分享：编辑很nice, 拒过一次又收了。 <br> 2017.05.07 投稿 <br> 2017.05.13 拒稿，给了四条修改意见 <br> 2017.07.07 修改后投稿 <br> 2017.07.14 under review <br> 2017.08.17 awaiting decision <br> 2017.08.19 小修，给一个月，三个审稿人，一共23条问题。 <br> 2017.09.16 修回 <br> 2017.09.18 under review <br> 2017.9.22 awaiting decision <br> 2017.9. 23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=412, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71002090938, createdName=200404334_92228262, createdTime=Mon Sep 25 10:14:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522268, encodeId=259b522268eb, content=由于是自己第一篇SCI，所以比较激动，等的时间也比较长，具体时间如下： <br> 2015.11.04日投稿 <br> 2016.03.11日外审结果小修 <br> 2016.04.09日修回又外审 <br> 2016.05.09日外审结果继续小修（问题特别少） <br> 2016.05.10日修回 <br> 2015.05.10日最后小修（改些单位，参考文献之类的，要求立即修回） <br> 2015.05.10日收到邮件立即修回 <br> 2015.05.10日修回后半小时收到邮件，接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=494, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78ea1723216, createdName=香坊吴彦祖, createdTime=Wed May 11 12:51:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516095, encodeId=fec8516095af, content=谁能发一个这个期刊的投稿须知以及详细的投稿要求给我呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd1967747, createdName=adolf1984, createdTime=Sun Oct 18 16:53:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=514974, encodeId=2b1b5149e492, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：5月11号的时候专门过来吐槽过一次，5月28号发来邮件通知小修，大喜~后忙于各种事项。今日无意搜到见刊，特来反馈。感觉语言要求一般，自己写完老板改了几遍就投了，没有要求润色。强调，内容不在多，在新颖。感恩，共勉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10f01624414, createdName=zxyzxyzxy, createdTime=Tue Sep 01 09:59:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513831, encodeId=df6c513831f6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：7.22投稿，7.23拒稿。说语言需要润色。这个稿件之前也有投过其他杂志，没有要求润色。稿件编号1400多。反正没有本网站描述的那么容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=473, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60151622867, createdName=Kaiduan1990, createdTime=Fri Jul 24 19:03:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2021-12-29 桑晒麦拉

    如何判断两种药物之间是协同作用还是相加作用？

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1094681, encodeId=4987109468180, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1094682, encodeId=67e5109468292, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847123, encodeId=918f84e12376, content=2018.06.01 投稿 <br> 2018.06.06 under review <br> 2018.07.25 accept subject to minor revision (25-jul-2018)，给一个月，二个审稿人，一共10来条问题。 <br> 2018.08.17 修回 <br> 2018.08.17 under review <br> 2018.09.04 accept (04-sep-2018) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Sun Sep 09 09:04:18 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552370, encodeId=bfa65523e044, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:51:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552369, encodeId=330f55236909, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:50:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547583, encodeId=91e854e583e1, content=审稿速度:3.0<br>经验分享：编辑很nice, 拒过一次又收了。 <br> 2017.05.07 投稿 <br> 2017.05.13 拒稿，给了四条修改意见 <br> 2017.07.07 修改后投稿 <br> 2017.07.14 under review <br> 2017.08.17 awaiting decision <br> 2017.08.19 小修，给一个月，三个审稿人，一共23条问题。 <br> 2017.09.16 修回 <br> 2017.09.18 under review <br> 2017.9.22 awaiting decision <br> 2017.9. 23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=412, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71002090938, createdName=200404334_92228262, createdTime=Mon Sep 25 10:14:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522268, encodeId=259b522268eb, content=由于是自己第一篇SCI，所以比较激动，等的时间也比较长，具体时间如下： <br> 2015.11.04日投稿 <br> 2016.03.11日外审结果小修 <br> 2016.04.09日修回又外审 <br> 2016.05.09日外审结果继续小修（问题特别少） <br> 2016.05.10日修回 <br> 2015.05.10日最后小修（改些单位，参考文献之类的，要求立即修回） <br> 2015.05.10日收到邮件立即修回 <br> 2015.05.10日修回后半小时收到邮件，接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=494, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78ea1723216, createdName=香坊吴彦祖, createdTime=Wed May 11 12:51:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516095, encodeId=fec8516095af, content=谁能发一个这个期刊的投稿须知以及详细的投稿要求给我呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd1967747, createdName=adolf1984, createdTime=Sun Oct 18 16:53:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=514974, encodeId=2b1b5149e492, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：5月11号的时候专门过来吐槽过一次，5月28号发来邮件通知小修，大喜~后忙于各种事项。今日无意搜到见刊，特来反馈。感觉语言要求一般，自己写完老板改了几遍就投了，没有要求润色。强调，内容不在多，在新颖。感恩，共勉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10f01624414, createdName=zxyzxyzxy, createdTime=Tue Sep 01 09:59:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513831, encodeId=df6c513831f6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：7.22投稿，7.23拒稿。说语言需要润色。这个稿件之前也有投过其他杂志，没有要求润色。稿件编号1400多。反正没有本网站描述的那么容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=473, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60151622867, createdName=Kaiduan1990, createdTime=Fri Jul 24 19:03:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2021-12-28 MS68862005

    如果文章发表了未提供ORCIDID如何添加？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1094681, encodeId=4987109468180, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1094682, encodeId=67e5109468292, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847123, encodeId=918f84e12376, content=2018.06.01 投稿 <br> 2018.06.06 under review <br> 2018.07.25 accept subject to minor revision (25-jul-2018)，给一个月，二个审稿人，一共10来条问题。 <br> 2018.08.17 修回 <br> 2018.08.17 under review <br> 2018.09.04 accept (04-sep-2018) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Sun Sep 09 09:04:18 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552370, encodeId=bfa65523e044, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:51:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552369, encodeId=330f55236909, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:50:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547583, encodeId=91e854e583e1, content=审稿速度:3.0<br>经验分享：编辑很nice, 拒过一次又收了。 <br> 2017.05.07 投稿 <br> 2017.05.13 拒稿，给了四条修改意见 <br> 2017.07.07 修改后投稿 <br> 2017.07.14 under review <br> 2017.08.17 awaiting decision <br> 2017.08.19 小修，给一个月，三个审稿人，一共23条问题。 <br> 2017.09.16 修回 <br> 2017.09.18 under review <br> 2017.9.22 awaiting decision <br> 2017.9. 23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=412, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71002090938, createdName=200404334_92228262, createdTime=Mon Sep 25 10:14:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522268, encodeId=259b522268eb, content=由于是自己第一篇SCI，所以比较激动，等的时间也比较长，具体时间如下： <br> 2015.11.04日投稿 <br> 2016.03.11日外审结果小修 <br> 2016.04.09日修回又外审 <br> 2016.05.09日外审结果继续小修（问题特别少） <br> 2016.05.10日修回 <br> 2015.05.10日最后小修（改些单位，参考文献之类的，要求立即修回） <br> 2015.05.10日收到邮件立即修回 <br> 2015.05.10日修回后半小时收到邮件，接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=494, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78ea1723216, createdName=香坊吴彦祖, createdTime=Wed May 11 12:51:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516095, encodeId=fec8516095af, content=谁能发一个这个期刊的投稿须知以及详细的投稿要求给我呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd1967747, createdName=adolf1984, createdTime=Sun Oct 18 16:53:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=514974, encodeId=2b1b5149e492, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：5月11号的时候专门过来吐槽过一次，5月28号发来邮件通知小修，大喜~后忙于各种事项。今日无意搜到见刊，特来反馈。感觉语言要求一般，自己写完老板改了几遍就投了，没有要求润色。强调，内容不在多，在新颖。感恩，共勉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10f01624414, createdName=zxyzxyzxy, createdTime=Tue Sep 01 09:59:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513831, encodeId=df6c513831f6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：7.22投稿，7.23拒稿。说语言需要润色。这个稿件之前也有投过其他杂志，没有要求润色。稿件编号1400多。反正没有本网站描述的那么容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=473, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60151622867, createdName=Kaiduan1990, createdTime=Fri Jul 24 19:03:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2018-09-09 ms9537892490195010

    2018.06.01 投稿
    2018.06.06 under review
    2018.07.25 accept subject to minor revision (25-jul-2018)，给一个月，二个审稿人，一共10来条问题。
    2018.08.17 修回
    2018.08.17 under review
    2018.09.04 accept (04-sep-2018)

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1094681, encodeId=4987109468180, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1094682, encodeId=67e5109468292, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847123, encodeId=918f84e12376, content=2018.06.01 投稿 <br> 2018.06.06 under review <br> 2018.07.25 accept subject to minor revision (25-jul-2018)，给一个月，二个审稿人，一共10来条问题。 <br> 2018.08.17 修回 <br> 2018.08.17 under review <br> 2018.09.04 accept (04-sep-2018) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Sun Sep 09 09:04:18 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552370, encodeId=bfa65523e044, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:51:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552369, encodeId=330f55236909, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:50:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547583, encodeId=91e854e583e1, content=审稿速度:3.0<br>经验分享：编辑很nice, 拒过一次又收了。 <br> 2017.05.07 投稿 <br> 2017.05.13 拒稿，给了四条修改意见 <br> 2017.07.07 修改后投稿 <br> 2017.07.14 under review <br> 2017.08.17 awaiting decision <br> 2017.08.19 小修，给一个月，三个审稿人，一共23条问题。 <br> 2017.09.16 修回 <br> 2017.09.18 under review <br> 2017.9.22 awaiting decision <br> 2017.9. 23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=412, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71002090938, createdName=200404334_92228262, createdTime=Mon Sep 25 10:14:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522268, encodeId=259b522268eb, content=由于是自己第一篇SCI，所以比较激动，等的时间也比较长，具体时间如下： <br> 2015.11.04日投稿 <br> 2016.03.11日外审结果小修 <br> 2016.04.09日修回又外审 <br> 2016.05.09日外审结果继续小修（问题特别少） <br> 2016.05.10日修回 <br> 2015.05.10日最后小修（改些单位，参考文献之类的，要求立即修回） <br> 2015.05.10日收到邮件立即修回 <br> 2015.05.10日修回后半小时收到邮件，接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=494, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78ea1723216, createdName=香坊吴彦祖, createdTime=Wed May 11 12:51:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516095, encodeId=fec8516095af, content=谁能发一个这个期刊的投稿须知以及详细的投稿要求给我呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd1967747, createdName=adolf1984, createdTime=Sun Oct 18 16:53:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=514974, encodeId=2b1b5149e492, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：5月11号的时候专门过来吐槽过一次，5月28号发来邮件通知小修，大喜~后忙于各种事项。今日无意搜到见刊，特来反馈。感觉语言要求一般，自己写完老板改了几遍就投了，没有要求润色。强调，内容不在多，在新颖。感恩，共勉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10f01624414, createdName=zxyzxyzxy, createdTime=Tue Sep 01 09:59:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513831, encodeId=df6c513831f6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：7.22投稿，7.23拒稿。说语言需要润色。这个稿件之前也有投过其他杂志，没有要求润色。稿件编号1400多。反正没有本网站描述的那么容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=473, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60151622867, createdName=Kaiduan1990, createdTime=Fri Jul 24 19:03:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2018-02-05 Enzyme-structure

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享：2017.9 投稿
    2018.1小修
    2018.2 接收

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1094681, encodeId=4987109468180, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1094682, encodeId=67e5109468292, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847123, encodeId=918f84e12376, content=2018.06.01 投稿 <br> 2018.06.06 under review <br> 2018.07.25 accept subject to minor revision (25-jul-2018)，给一个月，二个审稿人，一共10来条问题。 <br> 2018.08.17 修回 <br> 2018.08.17 under review <br> 2018.09.04 accept (04-sep-2018) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Sun Sep 09 09:04:18 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552370, encodeId=bfa65523e044, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:51:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552369, encodeId=330f55236909, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:50:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547583, encodeId=91e854e583e1, content=审稿速度:3.0<br>经验分享：编辑很nice, 拒过一次又收了。 <br> 2017.05.07 投稿 <br> 2017.05.13 拒稿，给了四条修改意见 <br> 2017.07.07 修改后投稿 <br> 2017.07.14 under review <br> 2017.08.17 awaiting decision <br> 2017.08.19 小修，给一个月，三个审稿人，一共23条问题。 <br> 2017.09.16 修回 <br> 2017.09.18 under review <br> 2017.9.22 awaiting decision <br> 2017.9. 23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=412, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71002090938, createdName=200404334_92228262, createdTime=Mon Sep 25 10:14:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522268, encodeId=259b522268eb, content=由于是自己第一篇SCI，所以比较激动，等的时间也比较长，具体时间如下： <br> 2015.11.04日投稿 <br> 2016.03.11日外审结果小修 <br> 2016.04.09日修回又外审 <br> 2016.05.09日外审结果继续小修（问题特别少） <br> 2016.05.10日修回 <br> 2015.05.10日最后小修（改些单位，参考文献之类的，要求立即修回） <br> 2015.05.10日收到邮件立即修回 <br> 2015.05.10日修回后半小时收到邮件，接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=494, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78ea1723216, createdName=香坊吴彦祖, createdTime=Wed May 11 12:51:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516095, encodeId=fec8516095af, content=谁能发一个这个期刊的投稿须知以及详细的投稿要求给我呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd1967747, createdName=adolf1984, createdTime=Sun Oct 18 16:53:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=514974, encodeId=2b1b5149e492, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：5月11号的时候专门过来吐槽过一次，5月28号发来邮件通知小修，大喜~后忙于各种事项。今日无意搜到见刊，特来反馈。感觉语言要求一般，自己写完老板改了几遍就投了，没有要求润色。强调，内容不在多，在新颖。感恩，共勉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10f01624414, createdName=zxyzxyzxy, createdTime=Tue Sep 01 09:59:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513831, encodeId=df6c513831f6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：7.22投稿，7.23拒稿。说语言需要润色。这个稿件之前也有投过其他杂志，没有要求润色。稿件编号1400多。反正没有本网站描述的那么容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=473, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60151622867, createdName=Kaiduan1990, createdTime=Fri Jul 24 19:03:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2018-02-05 Enzyme-structure

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享：2017.9 投稿
    2018.1小修
    2018.2 接收

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1094681, encodeId=4987109468180, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1094682, encodeId=67e5109468292, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847123, encodeId=918f84e12376, content=2018.06.01 投稿 <br> 2018.06.06 under review <br> 2018.07.25 accept subject to minor revision (25-jul-2018)，给一个月，二个审稿人，一共10来条问题。 <br> 2018.08.17 修回 <br> 2018.08.17 under review <br> 2018.09.04 accept (04-sep-2018) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Sun Sep 09 09:04:18 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552370, encodeId=bfa65523e044, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:51:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552369, encodeId=330f55236909, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:50:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547583, encodeId=91e854e583e1, content=审稿速度:3.0<br>经验分享：编辑很nice, 拒过一次又收了。 <br> 2017.05.07 投稿 <br> 2017.05.13 拒稿，给了四条修改意见 <br> 2017.07.07 修改后投稿 <br> 2017.07.14 under review <br> 2017.08.17 awaiting decision <br> 2017.08.19 小修，给一个月，三个审稿人，一共23条问题。 <br> 2017.09.16 修回 <br> 2017.09.18 under review <br> 2017.9.22 awaiting decision <br> 2017.9. 23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=412, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71002090938, createdName=200404334_92228262, createdTime=Mon Sep 25 10:14:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522268, encodeId=259b522268eb, content=由于是自己第一篇SCI，所以比较激动，等的时间也比较长，具体时间如下： <br> 2015.11.04日投稿 <br> 2016.03.11日外审结果小修 <br> 2016.04.09日修回又外审 <br> 2016.05.09日外审结果继续小修（问题特别少） <br> 2016.05.10日修回 <br> 2015.05.10日最后小修（改些单位，参考文献之类的，要求立即修回） <br> 2015.05.10日收到邮件立即修回 <br> 2015.05.10日修回后半小时收到邮件，接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=494, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78ea1723216, createdName=香坊吴彦祖, createdTime=Wed May 11 12:51:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516095, encodeId=fec8516095af, content=谁能发一个这个期刊的投稿须知以及详细的投稿要求给我呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd1967747, createdName=adolf1984, createdTime=Sun Oct 18 16:53:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=514974, encodeId=2b1b5149e492, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：5月11号的时候专门过来吐槽过一次，5月28号发来邮件通知小修，大喜~后忙于各种事项。今日无意搜到见刊，特来反馈。感觉语言要求一般，自己写完老板改了几遍就投了，没有要求润色。强调，内容不在多，在新颖。感恩，共勉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10f01624414, createdName=zxyzxyzxy, createdTime=Tue Sep 01 09:59:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513831, encodeId=df6c513831f6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：7.22投稿，7.23拒稿。说语言需要润色。这个稿件之前也有投过其他杂志，没有要求润色。稿件编号1400多。反正没有本网站描述的那么容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=473, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60151622867, createdName=Kaiduan1990, createdTime=Fri Jul 24 19:03:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2017-09-25 200404334_92228262

    审稿速度:3.0
    经验分享：编辑很nice, 拒过一次又收了。
    2017.05.07 投稿
    2017.05.13 拒稿，给了四条修改意见
    2017.07.07 修改后投稿
    2017.07.14 under review
    2017.08.17 awaiting decision
    2017.08.19 小修，给一个月，三个审稿人，一共23条问题。
    2017.09.16 修回
    2017.09.18 under review
    2017.9.22 awaiting decision
    2017.9. 23 接收

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1094681, encodeId=4987109468180, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1094682, encodeId=67e5109468292, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847123, encodeId=918f84e12376, content=2018.06.01 投稿 <br> 2018.06.06 under review <br> 2018.07.25 accept subject to minor revision (25-jul-2018)，给一个月，二个审稿人，一共10来条问题。 <br> 2018.08.17 修回 <br> 2018.08.17 under review <br> 2018.09.04 accept (04-sep-2018) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Sun Sep 09 09:04:18 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552370, encodeId=bfa65523e044, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:51:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552369, encodeId=330f55236909, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:50:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547583, encodeId=91e854e583e1, content=审稿速度:3.0<br>经验分享：编辑很nice, 拒过一次又收了。 <br> 2017.05.07 投稿 <br> 2017.05.13 拒稿，给了四条修改意见 <br> 2017.07.07 修改后投稿 <br> 2017.07.14 under review <br> 2017.08.17 awaiting decision <br> 2017.08.19 小修，给一个月，三个审稿人，一共23条问题。 <br> 2017.09.16 修回 <br> 2017.09.18 under review <br> 2017.9.22 awaiting decision <br> 2017.9. 23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=412, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71002090938, createdName=200404334_92228262, createdTime=Mon Sep 25 10:14:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522268, encodeId=259b522268eb, content=由于是自己第一篇SCI，所以比较激动，等的时间也比较长，具体时间如下： <br> 2015.11.04日投稿 <br> 2016.03.11日外审结果小修 <br> 2016.04.09日修回又外审 <br> 2016.05.09日外审结果继续小修（问题特别少） <br> 2016.05.10日修回 <br> 2015.05.10日最后小修（改些单位，参考文献之类的，要求立即修回） <br> 2015.05.10日收到邮件立即修回 <br> 2015.05.10日修回后半小时收到邮件，接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=494, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78ea1723216, createdName=香坊吴彦祖, createdTime=Wed May 11 12:51:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516095, encodeId=fec8516095af, content=谁能发一个这个期刊的投稿须知以及详细的投稿要求给我呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd1967747, createdName=adolf1984, createdTime=Sun Oct 18 16:53:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=514974, encodeId=2b1b5149e492, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：5月11号的时候专门过来吐槽过一次，5月28号发来邮件通知小修，大喜~后忙于各种事项。今日无意搜到见刊，特来反馈。感觉语言要求一般，自己写完老板改了几遍就投了，没有要求润色。强调，内容不在多，在新颖。感恩，共勉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10f01624414, createdName=zxyzxyzxy, createdTime=Tue Sep 01 09:59:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513831, encodeId=df6c513831f6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：7.22投稿，7.23拒稿。说语言需要润色。这个稿件之前也有投过其他杂志，没有要求润色。稿件编号1400多。反正没有本网站描述的那么容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=473, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60151622867, createdName=Kaiduan1990, createdTime=Fri Jul 24 19:03:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2016-05-11 香坊吴彦祖

    由于是自己第一篇SCI，所以比较激动，等的时间也比较长，具体时间如下：
    2015.11.04日投稿
    2016.03.11日外审结果小修
    2016.04.09日修回又外审
    2016.05.09日外审结果继续小修（问题特别少）
    2016.05.10日修回
    2015.05.10日最后小修（改些单位，参考文献之类的，要求立即修回）
    2015.05.10日收到邮件立即修回
    2015.05.10日修回后半小时收到邮件，接收

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1094681, encodeId=4987109468180, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1094682, encodeId=67e5109468292, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847123, encodeId=918f84e12376, content=2018.06.01 投稿 <br> 2018.06.06 under review <br> 2018.07.25 accept subject to minor revision (25-jul-2018)，给一个月，二个审稿人，一共10来条问题。 <br> 2018.08.17 修回 <br> 2018.08.17 under review <br> 2018.09.04 accept (04-sep-2018) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Sun Sep 09 09:04:18 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552370, encodeId=bfa65523e044, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:51:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552369, encodeId=330f55236909, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:50:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547583, encodeId=91e854e583e1, content=审稿速度:3.0<br>经验分享：编辑很nice, 拒过一次又收了。 <br> 2017.05.07 投稿 <br> 2017.05.13 拒稿，给了四条修改意见 <br> 2017.07.07 修改后投稿 <br> 2017.07.14 under review <br> 2017.08.17 awaiting decision <br> 2017.08.19 小修，给一个月，三个审稿人，一共23条问题。 <br> 2017.09.16 修回 <br> 2017.09.18 under review <br> 2017.9.22 awaiting decision <br> 2017.9. 23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=412, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71002090938, createdName=200404334_92228262, createdTime=Mon Sep 25 10:14:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522268, encodeId=259b522268eb, content=由于是自己第一篇SCI，所以比较激动，等的时间也比较长，具体时间如下： <br> 2015.11.04日投稿 <br> 2016.03.11日外审结果小修 <br> 2016.04.09日修回又外审 <br> 2016.05.09日外审结果继续小修（问题特别少） <br> 2016.05.10日修回 <br> 2015.05.10日最后小修（改些单位，参考文献之类的，要求立即修回） <br> 2015.05.10日收到邮件立即修回 <br> 2015.05.10日修回后半小时收到邮件，接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=494, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78ea1723216, createdName=香坊吴彦祖, createdTime=Wed May 11 12:51:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516095, encodeId=fec8516095af, content=谁能发一个这个期刊的投稿须知以及详细的投稿要求给我呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd1967747, createdName=adolf1984, createdTime=Sun Oct 18 16:53:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=514974, encodeId=2b1b5149e492, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：5月11号的时候专门过来吐槽过一次，5月28号发来邮件通知小修，大喜~后忙于各种事项。今日无意搜到见刊，特来反馈。感觉语言要求一般，自己写完老板改了几遍就投了，没有要求润色。强调，内容不在多，在新颖。感恩，共勉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10f01624414, createdName=zxyzxyzxy, createdTime=Tue Sep 01 09:59:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513831, encodeId=df6c513831f6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：7.22投稿，7.23拒稿。说语言需要润色。这个稿件之前也有投过其他杂志，没有要求润色。稿件编号1400多。反正没有本网站描述的那么容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=473, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60151622867, createdName=Kaiduan1990, createdTime=Fri Jul 24 19:03:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2015-10-18 adolf1984

    谁能发一个这个期刊的投稿须知以及详细的投稿要求给我呢？

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1094681, encodeId=4987109468180, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1094682, encodeId=67e5109468292, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847123, encodeId=918f84e12376, content=2018.06.01 投稿 <br> 2018.06.06 under review <br> 2018.07.25 accept subject to minor revision (25-jul-2018)，给一个月，二个审稿人，一共10来条问题。 <br> 2018.08.17 修回 <br> 2018.08.17 under review <br> 2018.09.04 accept (04-sep-2018) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Sun Sep 09 09:04:18 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552370, encodeId=bfa65523e044, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:51:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552369, encodeId=330f55236909, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:50:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547583, encodeId=91e854e583e1, content=审稿速度:3.0<br>经验分享：编辑很nice, 拒过一次又收了。 <br> 2017.05.07 投稿 <br> 2017.05.13 拒稿，给了四条修改意见 <br> 2017.07.07 修改后投稿 <br> 2017.07.14 under review <br> 2017.08.17 awaiting decision <br> 2017.08.19 小修，给一个月，三个审稿人，一共23条问题。 <br> 2017.09.16 修回 <br> 2017.09.18 under review <br> 2017.9.22 awaiting decision <br> 2017.9. 23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=412, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71002090938, createdName=200404334_92228262, createdTime=Mon Sep 25 10:14:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522268, encodeId=259b522268eb, content=由于是自己第一篇SCI，所以比较激动，等的时间也比较长，具体时间如下： <br> 2015.11.04日投稿 <br> 2016.03.11日外审结果小修 <br> 2016.04.09日修回又外审 <br> 2016.05.09日外审结果继续小修（问题特别少） <br> 2016.05.10日修回 <br> 2015.05.10日最后小修（改些单位，参考文献之类的，要求立即修回） <br> 2015.05.10日收到邮件立即修回 <br> 2015.05.10日修回后半小时收到邮件，接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=494, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78ea1723216, createdName=香坊吴彦祖, createdTime=Wed May 11 12:51:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516095, encodeId=fec8516095af, content=谁能发一个这个期刊的投稿须知以及详细的投稿要求给我呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd1967747, createdName=adolf1984, createdTime=Sun Oct 18 16:53:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=514974, encodeId=2b1b5149e492, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：5月11号的时候专门过来吐槽过一次，5月28号发来邮件通知小修，大喜~后忙于各种事项。今日无意搜到见刊，特来反馈。感觉语言要求一般，自己写完老板改了几遍就投了，没有要求润色。强调，内容不在多，在新颖。感恩，共勉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10f01624414, createdName=zxyzxyzxy, createdTime=Tue Sep 01 09:59:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513831, encodeId=df6c513831f6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：7.22投稿，7.23拒稿。说语言需要润色。这个稿件之前也有投过其他杂志，没有要求润色。稿件编号1400多。反正没有本网站描述的那么容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=473, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60151622867, createdName=Kaiduan1990, createdTime=Fri Jul 24 19:03:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2015-09-01 zxyzxyzxy

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享：5月11号的时候专门过来吐槽过一次，5月28号发来邮件通知小修，大喜~后忙于各种事项。今日无意搜到见刊，特来反馈。感觉语言要求一般，自己写完老板改了几遍就投了，没有要求润色。强调，内容不在多，在新颖。感恩，共勉！

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1094681, encodeId=4987109468180, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1094682, encodeId=67e5109468292, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847123, encodeId=918f84e12376, content=2018.06.01 投稿 <br> 2018.06.06 under review <br> 2018.07.25 accept subject to minor revision (25-jul-2018)，给一个月，二个审稿人，一共10来条问题。 <br> 2018.08.17 修回 <br> 2018.08.17 under review <br> 2018.09.04 accept (04-sep-2018) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Sun Sep 09 09:04:18 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552370, encodeId=bfa65523e044, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:51:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552369, encodeId=330f55236909, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：2017.9 投稿 <br> 2018.1小修 <br> 2018.2 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e3107791, createdName=Enzyme-structure, createdTime=Mon Feb 05 12:50:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547583, encodeId=91e854e583e1, content=审稿速度:3.0<br>经验分享：编辑很nice, 拒过一次又收了。 <br> 2017.05.07 投稿 <br> 2017.05.13 拒稿，给了四条修改意见 <br> 2017.07.07 修改后投稿 <br> 2017.07.14 under review <br> 2017.08.17 awaiting decision <br> 2017.08.19 小修，给一个月，三个审稿人，一共23条问题。 <br> 2017.09.16 修回 <br> 2017.09.18 under review <br> 2017.9.22 awaiting decision <br> 2017.9. 23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=412, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71002090938, createdName=200404334_92228262, createdTime=Mon Sep 25 10:14:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522268, encodeId=259b522268eb, content=由于是自己第一篇SCI，所以比较激动，等的时间也比较长，具体时间如下： <br> 2015.11.04日投稿 <br> 2016.03.11日外审结果小修 <br> 2016.04.09日修回又外审 <br> 2016.05.09日外审结果继续小修（问题特别少） <br> 2016.05.10日修回 <br> 2015.05.10日最后小修（改些单位，参考文献之类的，要求立即修回） <br> 2015.05.10日收到邮件立即修回 <br> 2015.05.10日修回后半小时收到邮件，接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=494, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78ea1723216, createdName=香坊吴彦祖, createdTime=Wed May 11 12:51:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516095, encodeId=fec8516095af, content=谁能发一个这个期刊的投稿须知以及详细的投稿要求给我呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd1967747, createdName=adolf1984, createdTime=Sun Oct 18 16:53:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=514974, encodeId=2b1b5149e492, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：5月11号的时候专门过来吐槽过一次，5月28号发来邮件通知小修，大喜~后忙于各种事项。今日无意搜到见刊，特来反馈。感觉语言要求一般，自己写完老板改了几遍就投了，没有要求润色。强调，内容不在多，在新颖。感恩，共勉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10f01624414, createdName=zxyzxyzxy, createdTime=Tue Sep 01 09:59:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513831, encodeId=df6c513831f6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：7.22投稿，7.23拒稿。说语言需要润色。这个稿件之前也有投过其他杂志，没有要求润色。稿件编号1400多。反正没有本网站描述的那么容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=473, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60151622867, createdName=Kaiduan1990, createdTime=Fri Jul 24 19:03:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2015-07-24 Kaiduan1990

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享：7.22投稿，7.23拒稿。说语言需要润色。这个稿件之前也有投过其他杂志，没有要求润色。稿件编号1400多。反正没有本网站描述的那么容易。

    0

共29条页码: 1/3页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分